While the antibody-drug conjugate Rova-T ultimately failed due to toxicity and efficacy issues, it was not a total loss. Its development laid the groundwork for future therapies by demonstrating that DLL3 is a legitimate, targetable antigen on SCLC cells, which paved the way for tarlatumab's success.
Tarlatumab represents a landmark achievement in a field with many failures. It is the only drug for second-line small cell lung cancer (SCLC) to ever demonstrate superiority over a therapeutic control arm (chemotherapy) in a randomized trial, improving survival, toxicity, and symptoms.
Real-world data shows higher rates of cytokine release syndrome (CRS) with tarlatumab than trials reported, especially in sicker patients. Despite this, the drug's risk-benefit profile is often better than chemotherapy for poor-performance patients, sometimes leading to durable, life-changing outcomes where no other options exist.
Recent NCCN guidelines have fundamentally changed second-line SCLC treatment. The previous standard, which based treatment on a >6 or <6 month chemotherapy-free interval, has been eliminated. Tarlatumab is now the single, category-one recommended therapy for all second-line patients, regardless of prior treatment timing.
Emerging data suggests SCLC molecular subtypes (e.g., ASCL1, POU2F3) correlate with tarlatumab response. However, this research is too premature to guide clinical decision-making. Clinicians are strongly cautioned against altering patient management based on this "intriguing but not yet proven" subtype data.